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Summary 
MRL-I/r/I/r mice spontaneously develop various manifestations of autoimmunity indnding an 
inflammatory arthropathy and immune complex glomerulonephritis. This study examines the 
role of nitric oxide, a molecule with proinfhmmatory actions,  in the pathogenesis  of MRL- 
1/r/I/r autoimmune disease. MRL-I/r/I/r mice excreted more urinary nitrite/nitrate (an in vivo 
marker of nitric oxide production) than did mice of normal strains and MILL-+/+  and B6- 
1/r/I/r congenic strains. In addition, MRL-I/r///r peritoneal macrophages had an enhanced capacity 
to produce nitric oxide in vitro as well as increased nitric oxide synthase activity, and certain 
tissues from MRL-I/r/I/r mice had increased expression of inducible nitric oxide synthase (NOS) 
mILNA and increased amounts of material immunoreactive for inducible NOS. Oral administration 
of NC-monomethyl-L-arginine,  a nitric oxide synthase inhibitor, prevented the development of 
glomerulonephritis and reduced the intensity of inflammatory arthritis in MRL-1/r/Ipr mice. 
By using interspecific backcross mice, the gene for inducible NOS (Nos~) was mapped to mouse 
chromosome 11. This chromosomal localization was different from those loci that we have previously 
demonstrated to be linked to enhanced susceptibility to renal disease in an MRL-I/r/l/r cross. 
However, the chromosomal location of the NOS gene was consistent with an insulin-dependent 
diabetes locus identified in an analysis of nonobese diabetic (NOD) mice. These results suggest 
that elevated nitric oxide production could be important in the pathogenesis of autoimmunity, 
and that treatments to block the production of nitric oxide or block its effects might be valuable 
therapeutically. 
M  RL-~r///r mice develop a spontaneous autoimmune dis- 
. ease characterized by lymphadenopatby, autoantibody 
production,  and  inflammatory  manifestations  including 
nephritis,  vasculitis, and arthritis (1, 2). Immune function 
abnormalities also include enhanced constitutive macrophage 
class II antigen expression (3), devated levels of IFN-% TNF, 
IL-1, and IL-6 in isolated kidney, lymph node, and spleen 
ceils (4-6), and an enhanced state of macrophage "activation" 
(3, 7). These disease  manifestations are a result of both a single 
gene mutation (I/r) of the Fas apoptosis gene on mouse chro- 
mosome 19 (8, 9) and background genes from the MRL swain 
(1,  9).  Although the MILL genes contributing to disease 
manifestations have not been identified, two loci contributing 
to renal disease have been mapped to regions of mouse chro- 
mosomes  7 and 12 (9). 
We have hypothesized that nitric oxide (NO) 1 plays a role 
1  Abbreviations used in th/s pape~ NMMA, NC-monoethybL-arginine; NO, 
nitric oxide; NOS, nitric oxide synthase; RFLV, restriction fragment length 
variants. 
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multifunctional molecule produced by diverse cell types, results 
from the conversion of L-arginine  to t-dtrulline and NO by 
the action of the enzyme nitric oxide synthase (NOS). NO 
has been noted to promote relaxation of smooth muscle, serve 
as a neurotransmitter,  cause staffs  and/or lysis of microbes 
and tumor cells,  and modulate function and differentiation 
of hematopoietic cells (10-14). NO also has potent proinflam- 
matory actions. Cell-derived NO, through interaction with 
superoxide, forms peroxynitrite which in turn may sponta- 
neously produce hydroxyl radical, a molecule with high poten- 
tial for cell and tissue injury and destruction  (15-17).  NO 
may increase vascular permeability in inflamed tissues (18). 
NO has also been shown to cause increased expression of TNF 
and IL-1 by cells, and to increase the potential of cells to pro- 
duce hydrogen peroxide (13,  14).  Also,  rabbit  and human 
chrondrocytes have been shown to produce NO and to ex- 
press iNOS in response to various cytokines and bacterial prod- 
ucts (19, 20), and investigators have noted increased concen- 
trations of the NO catabolite nitrite in synovial fluid and sera 
of patients  with  inflammatory  arthritis  (21).  McCartney- 
Francis et al. (22) have recently demonstrated that rats with 
arthritis induced by injection of streptococcal cell wall frag- 
ments have increased production of NO, and that adminis- 
tration of an inhibitor of NO synthase suppresses the arthritis. 
In the current studies, we have investigated the role of NO 
in lpr spontaneous autoimmune disease and determined the 
chromosomal location of iNOS.  Results demonstrate  that 
MtLL-lpr/Ipr  mice have devated levels of urinary excretion 
of nitrite/nitrate (a marker of NO production), and that their 
macrophages have an enhanced capacity for NO production. 
Certain tissues from MRL-lpr/Ipr mice have increased NOS 
activity, increased expression of iNOS mtLNA, and increased 
amounts of material immunoreactive for iNOS. Furthermore, 
blocking NO production with N~-monomethyl-t-arginine 
(NMMA) prevents the development oflnflanamatory nephritis 
and arthritis  in these mice. As determined by interspecific 
ha&cross experiments,  the gene for iNOS maps to mouse 
chromosome 11. This position is different from the location 
of Fas and those loci that we have previously demonstrated 
to be significantly linked to susceptibility to renal disease in 
MRL-Ipr/Ipr mice. 
Materials  and Methods 
M/ce.  C3H/HeJ (C3H), C3H/H3J-gld  (C3H-g/d),  BALB/cJ 
(BALB), C57BL/6J (]36), C57BL/6J-Ipr (B6-1pr/ipr), MILL/MpJ- 
Ipr (MtLI.,Ipr//pr), and MRL/MpJ (MgL-+/+) mice were origi- 
nally obtained from The Jackson Laboratory (Bar Harbor,  ME). 
Based on serological testing, these mice had no evidence of infec- 
tion with the following murine viruses and mycophsmas: pneu- 
monia virus of mice, mouse hepatitis virus, Sendal virus, ectromelia 
virus, mouse rotavirus, lymphocytic choriomeningitis  virus, reo- 
virus 3, Theiler's encephalomyelitis virus, minute virus of mice, 
Mycopiasma puimonis, and Mycoplasrna  arthritidis. Breeding to pro- 
duce selected F1 mice (see below) was done in our animal facility. 
Nitrite/Nitrate Assay.  Mice were  housed  in metabolic cages 
(three per cage) and fed deionized distilled sterile water and a defined 
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arginine and nitrate-free diet as noted before (23). Urine was col- 
lected into isopropanol  to inhibit bacterial growth.  Urinary ni- 
trite/nitrate  concentration was determined spectrophotometrically 
as described before (23). Determinations  were done in duplicate 
or triplicate. Total nitrate excretion was then calculated based on 
the concentration  and the urine volume. 
NOS Assay.  Spleen, fiver, kidneys, lymph nodes, and perito- 
neal cells were collected and quickly frozen in a dry ice-ethanol 
slurry in a buffer-protease inhibitor  cocktail containing  100/~M 
pbenylmethylsulfonyl fluoride, 5/~g/ml aprotinin, 1/~g/ml chymo- 
statin,  and 5/~g/ml pepstatin  A. The tissue cells were then dis- 
rupted with a pestle and repeated freeze-thaw cycles. Cytosol was 
collected after centrifugation,  and assayed  for protein and NOS ac- 
tivity using a modification of procedures noted before (24, 25). 
The  assay buffer  contained  50 raM  Hepes  (pH 7.5),  200 /zM 
NADPH, 1 mM dithiothreitol,  10/zM FAD, 100/~M tetrahydrobi- 
opterin,  and 10/~M L-arginine. We used L-arginine labeled with 
tritium in the guanidino position (NEC-453;  New England Nu- 
clear, Boston,  MA). 30 #1 of sample was used in a total reaction 
mixture  of 50 ~1. Samples were done in duplicate or triplicate. 
Messenger RNA  Analysis, Immunofluorescence, and  Imrnuno- 
b/ors.  Total  mRNA extraction and analysis was performed as noted 
before (6, 14). Indirect immunofluorescence was done as described 
before on tissues that were frozen quickly, sectioned, and fixed in 
cold acetone (26). Guinea pig serum containing  antibody specific 
for natural rat iNOS was from Dr. Stephen Gross (Oxford Univer- 
sity, Oxford, England). Normal guinea pig serum served as nega- 
tive control in experiments using the guinea pig antiserum. A rabbit 
polyclonal antiserum against murine ILAW264.7 iNOS was pro- 
duced by immunization  with an iNOS fusion protein  expressed 
in Eschoichia  coil cDNA encoding amino adds 1-224 of RAW264.7 
iNOS was amplified by RNA-PCK as described (25, 27), and in- 
serted into the pGEX2T vector (Pharmacia LKB, Piscataway, NJ). 
Gene expression from this plasmid construct results in the produc- 
tion of a protein  containing  26 kD of the carboxyl terminus  of 
glutathione-S-transferase fused to amino terminus of the encoded 
region of RAW264.7 iNOS. The iNOS fusion protein was purified 
f~om E. coli by a~inity chromatography on glutathinne-Sepharose 
(Pharmada LKB) (28) followed by preparative SDS polyacrylamide 
electmphoresis. The purified iNOS fusion protein in the acryhmide 
gel band was directly injected into New Zealand rabbits as described 
(29). Immunoprecipitates  and immunoblots using the antiserum 
were done as described before (29). For the immunoblots,  tissue 
from mouse organs was frozen rapidly in liquid nitrogen.  In im- 
munoprecipitation  experiments, the tissue was homogenized and 
extracts were precipitated with the rabbit anti-mouse iNOS an- 
tibody 
Chromosome  Localization.  C3H/HeJ-g/d and Mus spretus (Spain) 
mice and [(C3H/HeJ-g/d  x  Mus spretus)F1 x  C3H/HeJ-gld] in- 
terspecific backcross mice were bred and maintained as previously 
described (30). Mus spretus was chosen as the second parent in this 
cross because of the relative ease of detection of  informative restric- 
tion fragment length variants (RFLV) in comparison with crosses 
using conventional inbred laboratory  strains. 
DNA was isolated from mouse organs by standard techniques. 
DNA was digested  with  restriction  endonudeases,  and  10-/zg 
samples were electrophoresed in 0.9% agarose gels. DNA was trans- 
ferred Nytran membranes (Schl~er and Schuell, InK, Keene, NH), 
hybridized at 65~  and washed under stringent conditions, as pre- 
viously described (31). Clones used as probes in the current study 
included the mouse macrophage iNOS c.DNA (nudeotides 1-675 
[27, 32]), the avian  erythroblasmsis a and b (Erba and Erbb2) cDNAs, 
pAEPst0.45 and pAEBam0.5, respectively (33), and the p53 proto- 
oncogene cDNA (Trp53) (34). 
Autoimmunity Gene |ink2ge was determined by segregation analysis  (35). Gene  A  6 
order was determined by analyzing all haplotypes and minimizing 
crossover frequency between all genes that were determined to be  ~  s 
within a !i-kige group. This method resulted in determination of  "- 
the most likely gene order (36).  ~  I!~  4 
NMMA Treatment.  Groups  of 8-wk-old MRDlpr//pr mice were  ~  ~  z..s 
given either sterile  distilled  deionized  water or the water containing  ~  o  3 
50 mM NMMA for ad libitum consumption. NMMA was from  '- ,- 
CalBiochem-Behring  Corp. (San Diego, CA) and from Dr. Owen  ~  ~" 2 
Gri~th (Medical College of Wisconsin, Milwaukee, WI). Both  ~  1 
groups of mice were maintained on the defined nitrate-free diet  ~-~ 
described above. At weekly intervals, the mice were placed  in meta-  o 
boric cages and 24-h urine collections were obtained. Urinary ni- 
trate/nitrite was measured as described above, and urinary protein 
was measured  using the Bradford  assay  (Bio-Rad  hboratoties, Rich- 
mond, CA). After 10 wk of treatment,  the mice were bled and 
killed with removal of the kidneys and knee joints.  ,  12 
Serum anti-DNA  activity was determined by ELISA as previ- 
ously described (37). The kidneys were imbedded in paraffin, sec- 
tioned, and stained with hematoxylin and eosin. Knec joints were  ~  10 
decalcified in formic add, embedded into paraffin, sectioned, and  ~  ~.  8 
stained. Slides were then read  by a pathologist "blinded" as to the 
group of  origin. The amount of  kidney  and lmecjoint disease  present 
in each specimen were quantitated as noted before (38). Briefly,  ~  o  e 
glomeruli were graded for hypercellularity (0-4), hyperlobuhrity  ~  ~.  4 
(0-4), crescents (0-4), and necrosis (0-4).  A score was then de- 
E  2  rived by adding the grading of these features of  glomerular disease. 
Kidneys from normal BALB mice usually have scores from 0 to 
1. Vasculitis  was noted when present in medium size vessels in the 
kidney sections. The synovial score was derived by adding the 
grading of synovial  proliferation (0-3) and subsynovial  inflamma- 
tion (0-3). Knee  joints from normal BALB  mice usually have  scores 
from 0 to 0.5. 
Results 
Nitrite/Nitrate Excretion.  In animals consuming a nitrate- 
free diet, urinary excretion of nitrite/nitrate accurately reflects 
the endogenous production of NO (23).  To determine the 
production of NO in mice of different strains,  we analyzed 
urine collected daffy  under basal conditions. Fig. 1 A demon- 
strates that MILL-IF/I F  mice excrete more nitrite/nitrate than 
do C3H mice, when analyzed over a  10-d period at 3 mo 
of age. Likewise, when analyzed over time beginning at 6 
wk of age, MILL-lt,r/lpr mice excrete higher levels of nitrite/ 
nitrate than do B6 mice as the mice age (Fig.  1 B). Higher 
nitrate/nitrite  excretion  begins  at  '~10-12  wk  of age, 
paralleling that of proteinuria (Fig.  1 C). Oral administra- 
tion of 50 mM NMMA in water to the MILL-lpr/llyr mice 
reduced the high level nitrite/nitrate excretion (see bdow). 
This signifies that the nitrite/nitrate is a product of NOS, 
since NMMA is a specific inhibitor of the enzyme (10, 12, 
39).  Levds of nitrite/nitrate excretion in 5-mo-old mice of 
strains MILL-+/+  (0.8/~mol/mouse per d) and B6-1pr/lpr 
(1.2/~mol/mouse per d) (three mice in each group) were 
normal. These results indicate that neither the Ipr gene per 
se nor the MILL genetic background is adequate for the ex- 
pression of enhanced nitrite excretion, and that both the lpr 
gene and genetic factors in the MILL background are necessary. 
NO Production In  Vitro and Nitric Oxide  Synthase Con- 
tent.  Peritoneal macrophages from the normal BALB mice 
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Figure 1.  Enhanced  urinary nitrite/nitrate  excrerion in MILL-lpr/lpr 
mice. (A) Urinary  nitrite/nitrate  excretion in 5-mo-old  C3H and MTLL- 
I~/lpr mice (three mice in each group). (B) Urinary  nitrite/nitrate  excre- 
tion in B6 and MRL-lpr/Ipr  mice  over  a longer  period  of  time. The experi- 
ment began when the mice were 6 wk old (three mice in each group). 
(C) Urinary  protein in 136 and MILL-Ipr/lpr  (three mice in each group). 
These figures show results of one set of three experiments that showed 
comparable results. However,  in the results represented  in B and C, the 
initial mildly  elevated  levels  of excretion  in B6 mice  seen early  were noted 
in only  one of three experiments. 
had no enhancement of nitrite/nitrate production when treated 
with endotoxin or IFN-'y alone,  but the combination en- 
hanced the production greatly. In contrast, peritoneal macro- 
phages from MRL-Ipr/Ipr  mice had enhanced responses  to 
treatment with endotoxin and murine IFN-~/alone, as weU as with combined endotoxin/IFN-7 treatment (Fig.  2).  To 
determine if there was enhanced tissue iNOS mRNA expres- 
sion, RNA was extracted from organs from BALB and MR.L- 
lpr/~ mice, and then examined by Northern analysh  for iNOS 
mRNA expression (Fig.  3).  The iNOS mRNA (~4.7 kb 
in size) was noted in tissue from kidney and spleen from MRL- 
IF/I  F mice, but not in those from BALB mice. Various tissues 
and cells from MRL-IF/Ipr and BALB mice were extracted 
and analyzed for their abilities to convert [14C]l.-arginine (la- 
beled in the guanidino position) to [14C]L-dtrulline.  Perito- 
neal macrophages and spleen extracts from MRL-Ipr/lpr  mice 
displayed more NOS activity than did those from BALB mice, 
while the activity in kidney extracts was not different (Fig. 
4). By immunofluorescence  analysis using a rabbit anti-mouse 
iNOS  antibody, we noted no NOS  antigen expression in 
spleen, liver, and kidney from BALB mice, and none in liver 
or kidney from MRL-Ipr/Ipr mice. However, spleens  from 
MtLL-IF/I  F mice displayed large numbers of  ceUs containing 
the NOS antigen (Fig. 5 A). Comparable findings were noted 
when we used a monospecific guinea pig anti-rat inducible 
NOS antibody (data not shown). When tissue extracts were 
analyzed for iNOS antigen by immunoprecipitation and im- 
munoblotting techniques using a rabbit anti-mouse iNOS 
antibody, we did not detect antigen in extracts from organs 
of BALB  mice, although extracts from spleen and kidney 
tissues from MRL-Ipr/Ipr  mice had readily detectable antigen 
(Fig.  5 B). 
NMMA Treatment.  Groups of MRL-Ipr/Ipr  mice received 
either double distilled water (n  =  10) or water containing 
50 mM NMMA (n  =  9) beginning at 8 wk of age.  Both 
groups of mice received the defined nitrate free diet.  Mice 
were treated for a total of 10 wk. Mice in both groups ap- 
peared clinically normal. However, two mice in the NMMA 
group died during week 3 of treatment, leaving seven mice 
in the NMMA group for analysis. Extensive autopsies (in- 
cluding careful histological examinations and culturing of 
serum, urine, and organs) on these two mice and on a corn- 
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Figure  2.  Enhanced  capacity of peritoneal macrophages  from MRL- 
Ipr/lpr  mice to produce nitrite/nitrate in vitro. Resident peritoneal macro- 
phages were harvested from BALB or MRL-Ipr/lpr  mice and cultured as 
noted before (59) with the indicated additives  (50 ng/ml endotoxin; 50 
U/ml IFN-7). After 48 h of culture, culture supernatant nitrite/nitrate 
was determined. Means and standard errors of means of triplicate samples 
are displayed. This figure shows results of one of three experiments; all 
showed comparable patterns of results. 
Figure 3.  Increased  expression 
of mRNA  for  inducible  nitric 
oxide synthase  in samples from 
MRL-IF//F mice. Northern blot 
analysis  was done  on total  mRNA 
(20/~g/lane) extracted  from the 
indicated  tissues  and probed  with 
a cDNA for mouse  macrophage 
iNOS cDNA  (nudeotides  1-675). 
The top portion  shows  the results 
from the x-ray film after probing 
with the cDNA. The bottom por- 
tion disphys the same falter after 
removing tl~ iNOS cDNA prose, 
and reanalyzing with a probe for 
28S RNA as an indication of the 
equality  of mRNA loading. 
parable mouse that had received NMMA for 4 wk revealed 
no evidence of microbial infection or other evident cause of 
death. As shown in Fig. 6 A, administration of NMMA in 
the drinking water of MRL-lpr/lpr mice effectively blocked 
nitrate/nitrite excretion (and by inference nitric oxide produc- 
tion). Also, mice receiving NMMA excreted significantly less 
protein than did control mice; this difference  became apparent 
at week 5 of treatment (Fig.  6 B). 
Pathologic examination of the kidneys and knee joints of 
mice from the two groups of mice revealed significantly less 
disease in the NMMA-treated group. Renal disease as mea- 
sured by the renal score, and arthritis as measured by the sy- 
novial score were both significantly less in the NMMA group 
as compared with the control group (Hg. 7). There was min- 
imal  to  no  glomerular proliferation in  mice treated with 
NMMA, while all but one of the control mice had significant 
glomerular proliferation and hyperlobulation. The chronic 
interstitial lymphocytic infiltrate seen in the kidneys of all 
Ipr congenic mice (induding C3H-lpr/Ipr mice that do not 
develop glomerulonephritis) was present to comparable degrees 
in both control and NMMA-treated mice. Medium vessel 
vasculitis appears sporadicaUy  in the kidneys of  tmtreated MRL- 
lpr/Ipr mice with an overall incidence of 30%  (40).  Mild to 
moderate (1-2 +) medium vessd vasculitis was present in 3 
of 10 kidneys from mice in the control group. Mild vasculitis 
was seen in 1 of 7 kidneys from the NMMA-treated group. 
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Figure 4.  Increased expression 
of  NO synthase activity  in samples 
from  MRL-Ipr/Ipr mice.  NOS 
functional activity in extracts of 
peritoneal  macrophages  (Mac), 
spleen,  and  kidney from BALB 
and MRL-IFr/Ipr  mice. Rmtlts are 
presented on a log scale  as pico- 
moles t-citrulline  generated from 
L-arginine per milligram protein. 
Means  and  standard  errors  of 
means  of duplicate or triplicate 
samples are displayed. 
654  Nitric Oxide in Spontaneous  Autoimmunity Figure  5.  Demonstration ofiNOS antigen in 
tissues of  MRL-Ipr//~ mice. (tl) Immunofluores- 
cence of spleen (A and B) and lymph nodes (E 
and F) from BALB mice and from MRL-lpr/lpr 
mice (C and D  [spleen], and G and H  [lymph 
nodes]). A, C, E, and G are phase contrast views 
of tissue, and R/~ F, and H are fluorescent views 
of tissue. D  demonstrates several spleen cells 
staining positively for  iNOS  antigen.  Tissues 
reacted with normal rabbit serum instead of  rabbit 
anti-iNOS serum were negative. These photo- 
graphs are from one of two different e~miments 
performed; each showed comparable results. (B) 
Immunoblot of  immunoprecipitated  material from 
tissue extracts from BAI.B  and MRL-lpr//pr  mice. 
The lanes con~ining material of  MRL-Ipr//pr  mice 
spleen and kidney show positive reactions with 
bands at approximately 135 kD, whih all other 
hnes are negative. The bars at the right represent 
the positions of molecuhr mass markers. --  No-m.nt  / 
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Figure 6.  Effect  of NMMA mgesrton on mtnte/mtrate emaetion and 
protemuna m MRL-lpr/Ipr  mice  (/1) Urinary mmte/mtrate ea~'erton m 
MRL-Ipr/Ipr  mice receiving either water or 50 mM NMMA in water orally 
ad libttum. Urine determinations  were done on urines collected over a 
24-h penod from rmce (two per cage) at the tLmes  designated. (B) Pmtem- 
una m MRL-tpr/tpr mice recemng either water  or 50 mM NMMA m 
water orally ad hbltum. Unne determinations  were done on urines col- 
lected over a 24-h period from mice (two per cage) at the times desig- 
nated Unne nitntc/mtrate determmatiom were done on the samples col- 
lected at the designated time pomts (samples from five cages in the NO 
treatment group and four cages m the NMMA group). Means and start- 
dam errors of the means are displayed The observed differences  are statim- 
calty different (p <0.05) (Mann-Whitney U test) at all points after 77 d 
of agemA andB 
There was not a statistical  difference in vasculitis  between 
the two groups, but the small numbers of mice with vascu- 
lids makes it difficult to draw firm conclusions regarding the 
effects of NMMA on this aspect of inflammation.  Synovial 
Joint  Renal  AnIbDNA  Ab 
Figure 7.  Effect of  NMMA 
mgesuon of glomerulonephntis, 
arthnrts, and levels  of anrt-DNA 
antibodies in MILL-Ipr/tpr  mace 
Means  and  standard  errors  of 
means  of scores (for jmnt and 
renal) or of OD (for anti-double- 
stranded DNA antibody) are dis- 
played. The observed differences 
for jomt &sease and renM thsease 
are stattsrtcally different (f <0.05 
and p <0.022, respectwely, using 
the Mann-Whtmey U test), whde 
that for antt-DNA antibody level 
is not 
proliferation was significantly decreased in the mice treated 
with NMMA (Fig. 7). While only 3 of 7 mice in the NMMA- 
treated Stoup had abnormal kneejoints with mild to moderate 
syaovial proliferation and synovial inflammation, all 10 mice 
in the control water group had some degree  of synovial 
prolifzration and inRammation. Levels of serum anti-double- 
stranded DNA measured at age 18 wk in the two groups 
were essentially equivalent (Fig.  7). 
Mouse Clm~s~ttomal Localization and Fine Mapping.  To de- 
termine the chromosomal location of the gem encoding iNOS 
(designated N~)  and its relationship to disease susceptibility 
genes, we analyzed  a panel of DNA  samples from an in- 
tmped~ cross that has been ~h=,-zterized fi~r over S00 genetic 
m='lam throughout the genome.  The genetic markers in- 
d~ded~_ in this map span between 50 and 80 cM on each mouse 
autosome and the X  chromosome (for examples,  see refer- 
ences 41 and 42). Initially, DNA from the two parental mice 
[(C3H-&/d  x  .~  spretus)Ft] were digested with various re- 
striction endon~  and hybridized with Nosi eDNA probe 
to determine  RFLVs to allow haplotype analysis. Informative 
A  [] ￿9  ￿9  [] ￿9 
Dmm:i m 
[] ￿9  ￿9  [] m  [] 
B 
number of 
backcrmm  mice.  59  49  2 
[ Mouse dwemesome 11~ 
il 
0 -- --  Erbb 
154 ----  Adra-I 
242----  11-3 
260  --  Glur- 7 
35 7  --  Trp53 
38 4  --  Nosl 
41 1  Erba, Erbb-2, Rara 
47 2  -  Pkca 
51 6  T~mp-2 
cM 
]  2  I 
[]  C3H-g./d 
mC3H  -g/dx M  spretus 
7p14-plZB 
5q32-q35 
5qZ3-q31 
5q31-q33 
17p13  1 
17q21  1 
17pll  2-q12 
17q22-24 
17q 
Figure 8.  Linkage analysts of tNOS.  (,d) Segregauon of Noss among 
mouse distal mouse chromosome  11 locl m [(C3H-g/d  x  M~ spmus)Fl 
x C3H-g/d] backcross  nnce. Closed  boxes  represent the homozygous C3H 
pattern and open brines the Ft pattern.  The RFLVs and haplotype distn- 
burton of Erb2, and Erba m this mouse cross were reported previously 
(43). For Trp, RFLV were detected using BamH1 (C3H-&/d, 11.0 kb; Mus 
sprems, 18.0 kb). (B) Proposed mouse (and corresponding human) chro- 
mosomal localizataon. Erbb, avian  erythroblastosis oncogene B, epidermal 
growth factor receptor; Adra.1, adrenergic t~.eptor,  alpha-l;//-3, mter- 
lenkm  3; Glw-1,  glutamate receptor-I; Trp53, transf~mnarton-rehted pro- 
tern 53; Nosi, reducible mtnc oxide synthase; Erba, avian  erythroblastom 
oncogene A, thyroM hormone receptor; Erbb2, swan erythrobhstom on- 
cogene B-2, Ram, rertnmc add receptor, alpha, Pka, protein kmase C, 
alpha; Timp-2, tissue mhtbitor of metalloproteinases-2. 
656  Nitric Omde m Spontaneous Autotmmumty RFLVs were detected with PstI-restricted DNAs: C3H-g/d, 
6.5 kb; Mus spretus, 4.8 kb. 
Comparison of the haplotype distribution of Nosi indi- 
cated that in 111 of the 114 meiotic events examined, the 
Nosi locus cosegregated with the erythroblastosis hydroxylase 
locus (Erba),  a  locus previously mapped to distal mouse 
chromosome 11  in  this cross  (Fig.  8 A)  (43).  The best 
gene order plus or minus the standard deviation (35, 36) in- 
dicated the following relationships from proximal to distal: 
Trp53-2.6  •  1.5 cM-Nosi-2.6  +  1.5 cM-Erbb2/Erba 
(Fig.  8 B). 
Di~u~on 
We demonstrate here that MRL-ipr/ltrr mice spontaneously 
excrete high levels of urinary nitrite/nitrate that correspond 
temporally to the expression of inflammatory disease. Because 
there is no source of ingested nitrite/nitrate, the urinary ni- 
trite/nitrate represents an oxidation product of NO. MRL- 
Ipr/Ipr mice also have increased expression iNOS mRNA and 
of the functional enzyme NOS, and by immunofluorescence 
and immunoblot assays, they display increased amounts of 
iNOS antigen in spleen and kidney. Furthermore, treatment 
with oral NMMA either prevented or significantly decreased 
clinical autoimmune disease (glomerulonephritis and arthritis), 
without altering serum levels of anti-DNA antibodies. This 
result indicates that NO is a critical mediator in the develop- 
ment of the inflammation characteristic  of lpr disease, and 
that its production is not simply a reflection of nonspecific 
immune activation. The efficacy of NMMA suggests that 
treatments to reduce NO production or NO actions will be 
beneficial in inflammatory diseases. 
The cause(s) for the high levels of iNOS expression and 
NO production is not known. Mice with various infections 
have increased NO production (11, 12, 23). Although it is 
possible that the MRL-Ipr/lpr mice had a subclinical infec- 
tion, we feel this is unlikely since they were housed in iden- 
tical conditions to control strains  that had normal nitrate 
excretion,  they  had  no  serological  evidence  of viral  or 
mycoplasmal infection, and they did not appear to be clini- 
cally infected. 
MRL-Ipr/llYr mice have been shown before to display var- 
ious parameters of macrophage activation (4-8),  possibly 
reflecting high levels ofcytokines that may "activate" the mac- 
rophages within these animals. The main cytokines thought 
to  be involved are  IFN-%  TNF,  and  IL-1  (4-7).  These 
cytokines are responsible for increasing iNOS and inducing 
NO production in vivo (10-12). The lack of enhanced nitrite 
excretion in MRL-+/+  and B6-1pr/ltrr mice indicates  that 
both the Ipr gene and other genes in the MILL background 
are necessary for enhanced iNOS expression. 
By using interspecific backeross mapping techniques, we 
localized the gene for Nosi to distal mouse chromosome 11. 
The position of Nosi among other mouse chromosome 11 
loci (44) strongly suggests that this gene is located close to 
the position of the gene for mydoperoxidase, an oxidative 
enzyme which (like iNOS) is involved in inflammation and 
host defense. However, a GenBank search showed no homol- 
ogies in the sequences of iNOS and myeloperoxidase.  We 
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speculate that the close linkage of these genes may reflect some 
aspect of coordinate regulation. 
Based on known chromosomal analogies among positions 
on mouse and human chromosomes, the position of Nosi 
among other mouse chromosome 11 loci strongly suggests 
that the human homologue of this gene will be mapped to 
human chromosome 17 (44). The conserved linkage relation- 
ships suggest that this gene will map dose to BRCAI, a locus 
linked to familial breast and ovarian cancer on the long arm 
of human chromosome 17 (45, 46), and to the genes for mac- 
rophage inflammatory protein 1-cx and 1-B (44, 47, 48). A 
prior report has shown that the gene for constitutive NOS 
is on human chromosome 12 (49). The location of Nosi does 
not correspond to the sites of loci previously linked to renal 
disease susceptibility in MRL-lpr/IFr mice (9). This result sug- 
gests that enhanced iNOS expression and NO production, 
while critical for the development of disease, may not result 
from an abnormality in the iNOS gene, per se. 
Since MRL-Ipr/Ipr mice have been noted to have high levels 
of circulating immune complexes (DNA-anti-DNA  com- 
plexes), it is possible that the immune complexes could re- 
sult in activation of cells for enhanced iNOS activity and NO 
production. Mulligan et al. (50,  51) have noted that in rat 
models of IgG- or IgA-immune complex models of skin and 
lung inflammation, the NOS inhibitor NMMA can abro- 
gate inflammation. In association with the reduction ofinfl~na- 
marion by NMMA in IgG-immune complex lung disease, 
this compound also reduced the accumulation of alveolar fluid 
nitrite (51). Furthermore, NMMA administration markedly 
reduced the accumulation of alveolar macrophages in IgA- 
immune complex-induced  lung disease (50). Similarly, MRL- 
lpr/Ipr renal disease is immune complex mediated, primarily 
by deposition of anti-DNA antibodies. Despite the presence 
of high serum levels of anti-DNA antibodies, mice receiving 
NMMA did not develop glomerulonephritis. These studies 
further support the contention that NO may be important 
in immunologically induced inflammation. 
Other investigators have noted that NO produced by mac- 
rophages or pancreatic beta cells is capable of destroying the 
beta cells and contributing to the development of insulin- 
dependent diabetes  mellitus (52-54).  Kleemann et al.  (55) 
showed that adult rats of the insulin-dependent  diabetes-prone 
strain BB have pancreases that display iNOS mRNA and pro- 
tein coincident with macrophage infiltration and insulinitis, 
whereas normal rats do not. In a mouse model for insulin- 
dependent diabetes mdlitus (the NOD mouse [56]), researchers 
have found various genes that influence the development of 
diabetes. NOD mice have features of an autoimmune disease 
including anti-islet call antibodies and defects in T cell ac- 
tivity. Several genetic susceptibility loci have been mapped; 
these include areas in the major histocompatibility complex 
in mouse chromosome 17, and sites on chromosomes 1, 3, 
and 11 (52, 53). The ldd-5 gene maps to a region on chromo- 
some 1 that includes the genes for the IL-1 receptor and the 
Beg locus (53).  The Beg locus determines the natural resis- 
tance (mediated by macrophages) of mice to infection with 
intracellular microorganisms such as mycohacteria and listeria. 
Recently, a strong candidate for Bcg has been isolated and determined  to encode a protein with  structural  homology 
to membrane proteins  that  serve to transport  nitrate  (57). 
Vidal et al.  (57) have found defects in this gene in mice of 
strains that lack resistance to infection, and they have postu- 
lated that these defects might interrupt a system that allows 
eifector ceils to accumulate nitrate for conversion to NO, and 
thus be important  in microbial killing.  Idd-4,  a gene that 
influences the age at which NOD mice develop diabetes, maps 
to a region on chromosome 11 (58) that corresponds to the 
region where we map the gene for iNOS. Therefore, we sug- 
gest that iNOS is a strong candidate for an insulin depen- 
dent diabetes susceptibility gene. 
In two autoimmune diseases (that of NOD mice and that 
of MtLL-lpr/lpr mice), there are provocative relationships to 
NO and NOS.  NO could act as an effector in promoting 
inflammation in these mice. Possible proinflammatory effects 
of NO include an ability to increase vascular permeability 
in inflamed tissues (18), the secondary generation of destruc- 
tive free radicals  such as peroxynitrite and hydroxyl radical 
(15-17), and the induction of the inflammatory cytokines TNF 
and IL-1 (13, 14). Faneil et al. (21) demonstrated that humans 
with rheumatoid arthritis  and ostcoarthritis had increased levels 
of the NO catabolite nitrite in their synovial fluids and in 
their sera, suggesting a similar state of increased NO produc- 
tion as in mice with immune inflammation and arthritis. The 
regional or systemic use of agents that can inhibit the action 
of NO (e.g., heme-containing compounds such as hemoglobin 
or myoglobin [12], or agents that can block the production 
of NO (e.g.,  the iNOS inhibitor  NMMA [22, 39,  50, 51] 
we used here) could be valuable in therapy in humans with 
diseases  such as systemic lupus erythematosus,  rheumatoid 
arthritis,  or insulin-dependent  diabetes meilitus. 
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